



(51) International Patent Classification:

C07D 487/14 (2006.01) A61P 3/10 (2006.01)
C07D 487/12 (2006.01) A61P 29/00 (2006.01)
A61K 31/495 (2006.01) A61P 9/02 (2006.01)
A61K 31/50 (2006.01)

(21) International Application Number:

PCT/US2009/051879

(22) International Filing Date:

27 July 2009 (27.07.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/086,687	6 August 2008 (06.08.2008)	US
61/151,036	9 February 2009 (09.02.2009)	US
61/173,088	27 April 2009 (27.04.2009)	US

(71) Applicant (for all designated States except US): **LEAD THERAPEUTICS, INC.** [US/US]; 999 Bayhill Drive, Suite 130, San Bruno, California 94066 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WANG, Bing** [US/US]; 2041 Mandelay Place, San Jose, California 95138 (US). **CHU, Daniel** [US/US]; 3767 Benton Street, Santa Clara, California 95051 (US).

(74) Agents: **WILSON SONSINI GOODRICH & ROSATI** et al.; 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:


— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

27 May 2010

(54) Title: DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)



(I)

(57) Abstract: A compound having the structure set forth in Formula (I) and Formula (II) wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.